A conversation tool enters primary care for type 2 diabetes
A new cluster randomized clinical trial tested whether a simple agenda-setting kit could make type 2 diabetes care feel more workable for patients and clinicians in primary care. The intervention, called ASK, was built around a plain clinical problem: diabetes treatment often succeeds on paper while failing in daily life, where medications, diet changes, symptom concerns, work, finances, and competing priorities collide in the exam room.
The trial was conducted at a federally qualified health center in New Haven, Connecticut, and enrolled clinicians who prescribed medication for adults with T2D. Primary care physicians, nurse practitioners, and physician assistants were randomized in a 1:1 cluster design to either ASK plus usual care or usual care alone. Cluster randomization fit the intervention well because the tool was designed to alter conversations, not just individual medication choices. Once a clinician adopts a communication method, it tends to affect multiple patients, which makes contamination a real concern in standard patient-level randomization.
One sentence captures the intent of the study: the intervention tried to make diabetes care fit the person, not just the glucose number.
Why the ASK intervention was built around conversation, not directives
The ASK package included 14 conversation cards about life with diabetes and its treatment. Before the visit, patients were asked to choose zero to three cards they most wanted to discuss. That design matters clinically because diabetes management fails when the clinical agenda is set entirely by laboratory values, while the patient’s actual barriers remain unspoken. A structured prompt gives patients a way to raise concerns that can otherwise be crowded out by medication titration, time pressure, and the routine focus on HbA1c.
The study’s framing centered on care that fits: care that is sensible, desirable, and feasible for the person living with diabetes. In practical terms, that means treatment plans must account for more than glycemia. They also have to fit the patient’s capacity to implement them, the burden of appointments and medications, and the degree to which the plan disrupts work, family life, or emotional well-being. For patients with longstanding diabetes, those daily frictions can determine whether a regimen is followed at all.
The eligibility criteria narrowed the cohort to adults 18 years or older who were English- or Spanish-speaking and had HbA1c levels greater than 8%. Patients were excluded if the clinician judged that an HbA1c of 8% or lower was inconsistent with goals of care. That exclusion reflects an important bedside reality: glycemic targets are not universal. In some patients, a lower number may not be the right goal if comorbidity, frailty, treatment burden, or overall goals of care make intensification unreasonable.
Outcomes were designed to capture burden, distress, and glycemic control
The investigators chose a primary endpoint that moved beyond glucose alone. The main outcomes were the 6-month change from baseline in illness intrusiveness and HbA1c. Illness intrusiveness was measured with the Illness Intrusiveness Ratings Scale, which ranges from 13 to 91, with higher scores indicating greater disruption to life. HbA1c remained the metabolic anchor, but the trial recognized that a lower A1c does not necessarily mean better care if treatment makes daily life harder.
Secondary outcomes extended that same logic. Treatment burden was measured with the Treatment Burden Questionnaire, which ranges from 0 to 150, with higher scores indicating greater burden. Diabetes distress was measured with the 17-item Diabetes Distress Scale. Together, these measures reflect the lived experience of diabetes management: how much the condition intrudes, how much work the treatment requires, and how emotionally exhausting the disease has become. In chronic disease care, those domains often move independently of hemoglobin A1c.
The follow-up window lasted 6 months, which is long enough to detect meaningful change in many diabetes care processes while still short enough to preserve trial fidelity in a busy primary care setting. Data analysis ran from November 7, 2024, to August 13, 2026, after enrollment that stretched from February 16, 2023, to July 26, 2024.
A pragmatic attempt to change diabetes visits from the inside
The clinical logic behind ASK is straightforward. A card-based agenda tool may help patients articulate what blocks adherence, what they fear about therapy, and which aspects of diabetes care are most disruptive. Once those concerns are visible, the visit can shift from unilateral instruction to negotiation and shared planning. In diabetes care, that shift can be decisive because the most effective regimen on a spreadsheet still fails if it cannot be sustained in daily life.
This trial also speaks to the limits of standard primary care workflows. Short visits often force clinicians to choose between biomedical targets and patient priorities, and diabetes is especially vulnerable to that squeeze. A structured conversation tool tries to preserve both. It does not replace pharmacology, self-management education, or guideline-based intensification. It changes the sequence of the encounter so that treatment begins with the patient’s agenda rather than the clinician’s default script.
The supplied abstract stops after introducing the diabetes distress measure, so the efficacy findings are not included in the text available here. Even without the result section, the trial design itself is informative: investigators directly tested whether a low-cost communication aid could improve the fit of diabetes care while preserving glycemic attention. The real question embedded in the study is not only whether HbA1c changes, but whether patients can leave the visit with a plan that better matches the realities of living with diabetes.